Bailard, Inc. Adc Therapeutics Sa Transaction History

Bailard, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$19.29 - $31.51 $1.39 Million - $2.27 Million	-72,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$20.45 - $30.0 $222,905 - $327,000	-10,900 Reduced 13.15%	72,000 $1.96 Million
Q2 2021 Aug 13, 2021	BUY	$20.38 - $27.04 $548,222 - $727,376	26,900 Added 48.04%	82,900 $2.02 Million
Q1 2021 May 13, 2021	BUY	$22.75 - $34.05 $1.27 Million - $1.91 Million	56,000 New	56,000 $1.37 Million

55M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $155M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.